Folate, homocysteine, endothelial function and cardiovascular disease

被引:198
作者
Moat, SJ [1 ]
Lang, D [1 ]
McDowell, IFW [1 ]
Clarke, ZL [1 ]
Madhavan, AK [1 ]
Lewis, MJ [1 ]
Goodfellow, J [1 ]
机构
[1] Cardiff Univ, Wales Heart Res Inst, Cardiovasc Sci Res Grp, Cardiff CF14 4XN, S Glam, Wales
关键词
folate; homocysteine; endothelial function; nitric oxide (NO); cardiovascular disease (CVD); flow mediated dilatation (FMD);
D O I
10.1016/j.jnutbio.2003.08.010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Evidence reported from numerous clinical studies over the past decade has revealed an association between increased plasma total homocysteine (tHcy) concentrations and cardiovascular disease (CVD). In addition, epidemiological studies have identified an inverse association between blood folate concentrations, folate intake and cardiovascular endpoints, that are independent of homocysteine. Folic acid supplementation can lower plasma tHcy concentrations safely and inexpensively. Furthermore, folic acid can reverse endothelial dysfunction observed in patients with CVD. This reversal in endothelial dysfunction with folic acid has been shown to be independent of plasma tHcy lowering, suggesting that folate has pleiotropic effects on the vasculature other than homocysteine lowering. In vitro evidence demonstrates that 5-methyltetrahydrofolate (5MeTHF) the main circulating metabolite of folate, can increase nitric oxide production and can directly scavenge superoxide radicals. The potential beneficial role of folic acid supplements on vascular disease are currently being tested in randomized placebo controlled studies. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:64 / 79
页数:16
相关论文
共 102 条
[1]   Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction [J].
Al Suwaidi, J ;
Hamasaki, S ;
Higano, ST ;
Nishimura, RA ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 2000, 101 (09) :948-954
[2]   RELATION OF SERUM HOMOCYSTEINE AND LIPOPROTEIN(A) CONCENTRATIONS TO ATHEROSCLEROTIC DISEASE IN A PROSPECTIVE FINNISH POPULATION-BASED STUDY [J].
ALFTHAN, G ;
PEKKANEN, J ;
JAUHIAINEN, M ;
PITKANIEMI, J ;
KARVONEN, M ;
TUOMILEHTO, J ;
SALONEN, JT ;
EHNHOLM, C .
ATHEROSCLEROSIS, 1994, 106 (01) :9-19
[3]  
Baker F, 2002, CIRCULATION, V106, P741
[4]  
Bellamy MF, 1999, EUR J CLIN INVEST, V29, P659, DOI 10.1046/j.1365-2362.1999.00527.x
[5]   Power shortage: Clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour [J].
Bostom, AG ;
Selhub, J ;
Jacques, PF ;
Rosenberg, IH .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (02) :133-139
[6]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[7]   Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease -: The result of a meta-analysis [J].
Brattström, L ;
Wilcken, DEL ;
Öhrvik, J ;
Brudin, L .
CIRCULATION, 1998, 98 (23) :2520-2526
[8]  
Brattström L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894
[9]   Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls [J].
Bunout, D ;
Petermann, M ;
Kirsch, S ;
de la Maza, P ;
Suazo, M ;
Barrera, G ;
Kauffman, R .
NUTRITION, 2000, 16 (06) :434-438
[10]   The T allele of the C677T 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism may protect endothelial function in young, normal subjects [J].
Butler, R ;
Morris, AD ;
Struthers, AD .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (01) :193-194